Logo Image
|Articles|January 8, 2015

Mixed Results for Biogen Idec’s Neuroprotective Drug

Biogen Idec’s investigational monoclonal antibody met its primary endpoints in a recent Phase II for the treatment of acute optic neuritis.

 

Biogen Idec announced on Jan. 8, 2015 that its anti-LINGO-1 medication for the treatment of acute optic neuritis (AON) demonstrated evidence of biological repair in the eyes of those suffering from inflammation of the optic nerve. Although the anti-LINGO-1 showed an improvement in optic nerve conduction between the visual cortex and the brain-the study’s primary endpoint-it showed no effect on secondary endpoints, which focused on the improvement of thickness of the retinal layers and visual acuity.

Although the study met its primary endpoints, and there was a 34% improvement in eye nerve conduction for those who completed the study, when study dropouts were included, the results were no longer significant, reportsForbes’ Matthew Herper. Evercore ISI analyst Mark Schoenebaum says the data are “encouraging, but certainly not definitive.”

Biogen Idec discovered anti-LINGO in multiple animal models of demyelination. The monoclonal antibody-based drug works by blocking LINGO-1, a protein expressed in the central nervous system that is known to negatively regulate axonal myelination and regeneration. According to the company, LINGO-1 promotes myelin repair and regeneration.

Acute optic neuritis is characterized by loss of the myelin sheath surrounding the optic nerve and axonal injury. Because optic neuritis is highly associated with relapsing forms of multiple sclerosis (MS), and Biogen is currently testing the drug for this indication in a Phase II trial dubbed SYNERGY, analysts believe it could be promising therapy for progressive forms of MS. Data from the SYNERGY trial are anticipated in 2016.

Sources:
Forbes
Biogen Idec

Related to this article

View more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more